Linc

Linc FCF Growth

The Year-over-Year Free Cash Flow Growth of Linc (LINC.ST) as of Nov 20, 2026 is -100.00 %. In the previous year, Year-over-Year Free Cash Flow Growth was 136.84 % — a change of -173.08% (lower).

FCF Growth

-100.00 %

YoY

-173.08%

Last updated:

Year-over-Year Free Cash Flow Growth of Linc is 2025 -100.00 % . Year-over-Year Free Cash Flow Growth of Linc was 2024 136.84 % . It decreases by -173.08% lower compared to the previous year.

The Linc FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
105.97 SEK
Jan 1, 2020
-1,345.83 SEK
Jan 1, 2021
-2,319.25 SEK
Jan 1, 2022
35.52 SEK
Jan 1, 2023
64.69 SEK
Jan 1, 2024
136.84 SEK
Jan 1, 2025
-100.00 SEK
The Linc FCF Growth history
YEARFCF GrowthYoY
-100.00 %-173.08%
136.84 %+111.54%
64.69 %+82.10%
35.52 %-101.53%
-2,319.25 %+72.33%
-1,345.83 %-1,369.95%
105.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Year-over-Year Free Cash Flow Growth of Linc is -100.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Linc since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Linc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Linc

All Key Metrics — Linc